Regeneron is playing catch-up in the BCMAxCD3 class with Johnson & Johnson’s Tecvayli (teclistamab) and Pfizer’s Elrexfio ...

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' ...

The PrEPVacc trial in East and Sothern Africa is currently the only large-scale HIV vaccine efficacy trial being conducted in ...

At the start of this year, Aeglea BioTherapeutics was looking like it may go out of business. Now, rebranded as Spyre ...

This year, Joel Morse, Curavit’s CEO and founder, and Rachel Rangel, clinical trial specialist, share their predictions for ...

Historically, the pharmaceutical industry has been slow to adopt digital business models. This is because the industry is ...

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib ...

Which is why I say well done, Pfizer! I was delighted to read the recent news from Pfizer announcing the launch of their ...

Eleven new digital health start-ups have graduated from PharmStars’ twice-yearly education and mentoring programme, with the ...

The offer of JPY 8,620 ($58.56) per share offer is a 50% premium on Taisho’s average closing share price in the prior six ...

The third trial (INAVO122) is comparing the combination of inavolisib with Roche’s HER2-targeting drug Phesgo (pertuzumab ...

Aqemia says its Launchpad engine differs from others being used by industry as it is almost entirely ‘in silico’, i.e. it ...